Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

NCT02457598 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

203

Enrollment

INDUSTRY

Sponsor class

Stopped The goal of the study was to improve tolerability while maintaining or increasing efficacy. The results of this study showed no efficacy advantage although the combinations were well tolerated.

Conditions

B-cell Malignancies

Interventions

DRUG: Tirabrutinib
DRUG: Idelalisib
DRUG: Entospletinib
DRUG: Obinutuzumab

Sponsor

Gilead Sciences